Dr. Jun Gong, MD
Claim this profileCedars-Sinai Medical Center
About Jun Gong, MD
Education:
- Earned an MD from New York Medical College in 2008.
- Completed Internship and Residency at Cedars-Sinai Medical Center by 2013.
- Undertook a Fellowship at City of Hope Comprehensive Cancer Center in 2015.
Experience:
- Board-certified in Internal Medicine/Hematology, General Internal Medicine, and Internal Medicine/Oncology by the American Board of Internal Medicine.
- Has 15 years of experience as a medical oncologist and researcher at Cedars-Sinai Medical Center.
- Specializes in gastrointestinal and neuroendocrine malignancies, as well as urologic oncology.
Area of expertise
Colorectal Cancer
Jun Gong, MD has run 6 trials for Colorectal Cancer. Some of their research focus areas include:
Colon Cancer
Jun Gong, MD has run 5 trials for Colon Cancer. Some of their research focus areas include:
Affiliated Hospitals
Cedars-Sinai Medical Center
Tower Cancer Research Foundation
Clinical Trials Jun Gong, MD is currently running
Apalutamide + Carotuximab
for Prostate Cancer
This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.
Recruiting
1 award
Phase 2
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting
1 award
Phase 2 & 3
20 criteria
More about Jun Gong, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Jun Gong, MD has experience with
- Nivolumab
- Gemcitabine
- L-glutamine
- Nab-paclitaxel
- Ketorolac Tromethamine
- Regorafenib
Breakdown of trials Jun Gong, MD has run
Colorectal Cancer
Colon Cancer
Pancreatic Cancer
Rectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jun Gong, MD specialize in?
Jun Gong, MD focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are BRAF negative.
Is Jun Gong, MD currently recruiting for clinical trials?
Yes, Jun Gong, MD is currently recruiting for 7 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Jun Gong, MD has studied deeply?
Yes, Jun Gong, MD has studied treatments such as Nivolumab, Gemcitabine, L-glutamine.
What is the best way to schedule an appointment with Jun Gong, MD?
Apply for one of the trials that Jun Gong, MD is conducting.
What is the office address of Jun Gong, MD?
The office of Jun Gong, MD is located at: Cedars-Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars-Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.